XML 29 R24.htm IDEA: XBRL DOCUMENT
v3.24.3

Commitments and Contingencies - Additional Information (Details) - USD ($) |  |  |  |  |  | 3 Months Ended | 9 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 20, 2023 | Aug. 14, 2023 | Mar. 17, 2023 | Aug. 17, 2015 | Jan. 13, 2015 | Sep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023 | Apr. 03, 2023 | Oct. 22, 2019 | Aug. 24, 2004
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | $ 143,000 | $ 3,656,000 | $ 448,000 | $ 15,346,000 |  |  |
Revenue |  |  |  |  |  | 0 | 0 | 6,000 | 4,000 |  |  |
Unspecified monetary damages |  |  | $ 3,200,000 |  |  |  |  |  |  |  |  |
Loss contingency, name of plaintiff |  |  | KBI Biopharma |  |  |  |  |  |  |  |  |
Litigation expense | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |
MD Anderson Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Number of warrants |  |  |  |  |  |  |  |  |  |  | 22,222 |
Warrant exercise per share |  |  |  |  |  |  |  |  |  |  | $ 0.15 |
Warrant expiry date |  |  |  |  |  |  |  |  |  |  | Dec. 31, 2026 |
MD Anderson Agreement and Worldwide License [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
License agreement commencing date |  |  |  |  | Jan. 13, 2015 |  |  |  |  |  |  |
MD Anderson License and the Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement of historical costs |  |  |  |  |  |  |  |  |  |  | $ 20,000,000 |
Quarterly expense incurred |  |  |  |  |  | 0 | 200,000 | 0 | 700,000 |  |  |
Aggregate potential benchmark payments |  |  |  |  |  |  |  |  |  |  | 36,500,000 |
Payments due prior to the first marketing approval |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |
CRADA Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination date |  | Oct. 13, 2023 |  |  |  |  |  |  |  |  |  |
Annual expense incurred |  |  |  |  |  | 0 | 0 | 0 | 500,000 |  |  |
The University of Texas MD Anderson Cancer Center and The Texas A & M University System [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Milestone maximum payment |  |  |  |  |  |  |  |  |  |  |  | $ 4,500,000
The University of Texas MD Anderson Cancer Center and The Texas A & M University System [Member] | Royalty [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Payment under license agreement |  |  |  |  |  | 0 | 0 | 0 | 0 |  |  |
License Agreement with the National Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
License expense |  |  |  |  |  | 0 | 10,000.00 | 0 | 500,000 |  |  |
Collaboration Agreement with Solasia Pharma KK [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 0 | 0 | 0 | 0 |  |  |
Collaboration Agreement with Solasia Pharma KK [Member] | Royalty [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 0 | $ 0 | 6,000 | $ 4,000 |  |  |
M D Anderson License and the Two Thousand Fifteen Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Clinical expenses |  |  |  |  |  | $ 0 |  | $ 0 |  |  |  |
Intrexon Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Annual license fee |  |  |  |  |  |  |  |  |  | $ 75,000 |  |
Minimum [Member] | MD Anderson License and the Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  | $ 15,000,000 |  |  |  |  |  |  |  |
Maximum [Member] | MD Anderson License and the Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |

X
- Definition Payments due prior to the first marketing approval for TCR products. + References No definition available. + Details
Name: | tcrt_AccrualsPriorToFirstMarketingApproval
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate Amount Potentially Reimburseable Amount. + References No definition available. + Details
Name: | tcrt_AggregateAmountPotentiallyReimburseableAmount
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate potential benchmark payments. + References No definition available. + Details
Name: | tcrt_AggregatePotentialBenchmarkPayments
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Termination Date of CRADA Agreement + References No definition available. + Details
Name: | tcrt_AgreementTerminationDate
Namespace Prefix: | tcrt_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Annual expense incurred. + References No definition available. + Details
Name: | tcrt_AnnualExpenseIncurred
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual License Fees + References No definition available. + Details
Name: | tcrt_AnnualLicenseFees
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Clinical expenses. + References No definition available. + Details
Name: | tcrt_ClinicalExpenses
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Commitments and Contingencies Disclosure [Line Items] + References No definition available. + Details
Name: | tcrt_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix: | tcrt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement commencing date. + References No definition available. + Details
Name: | tcrt_LicenseAgreementCommencingDate
Namespace Prefix: | tcrt_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense related to License payments. + References No definition available. + Details
Name: | tcrt_LicenseExpense
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments maximum amount. + References No definition available. + Details
Name: | tcrt_MilestonePaymentsMaximumAmount
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment under license agreement. + References No definition available. + Details
Name: | tcrt_PaymentUnderLicenseAgreement
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Quarterly expense incurred. + References No definition available. + Details
Name: | tcrt_QuarterlyExpenseIncurred
Namespace Prefix: | tcrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Identifies the plaintiff in the lawsuit. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyNameOfPlaintiff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |